CAJ | 학술논문

目的探讨化疗中期及治疗结束后18F-脱氧葡萄糖(FDG) PET-CT对T细胞淋巴瘤(TCL)患者预后评估的价值.方法回顾性分析经病理确诊的50例TCL患者,在化疗中期及治疗结束后18F-FDG PET-CT影像特点.50例患者中,12例于化疗中期行PET-CT检查,19例于化疗中期及治疗结束后均行PET-CT检查,19例于治疗结束后行PET-CT检查.根据PET-CT检查结果将患者分为PET-CT阳性组和阴性组,经过随访31(4～86)个月,分别计算各组患者的无进展生存(PFS)期及总体生存(OS)期,采用Kaplan-Meier生存分析法进行生存分析,各组间的PFS率及OS率的比较采用Fisher确切概率法.结果 31例化疗中期18F-FDG PET-CT显像结果阳性患者19例,阴性患者12例,阳性者和阴性者中位PFS期分别为8和30个月,1年PFS率分别为21.1％(4/19)和100.0％(12/12),差异有统计学意义(P＜0.01);中位OS期分别为16和36个月,3年OS率分别为10.5％(2/19)和66.7％(8/12),差异有统计学意义(P＜0.01).治疗结束后18F-FDG PET-CT显像结果阳性患者16例,阴性患者22例,阳性者和阴性者中位PFS期分别为10和32个月,1年PFS率分别为12.5％(2/16)和95.5％(21/22),差异有统计学意义(P＜0.01);中位OS期分别为20和41个月,3年OS率分别为12.5％(2/16)和54.5％(12/22),差异有统计学意义(P＜0.01).结论 TCL患者化疗中期及治疗结束后18F-FDG PET-CT检查结果对监测疗效及判断预后具有重要意义.
목적 탐토화료중기급치료결속후18F-탈양포도당(FDG) PET-CT대T세포림파류(TCL)환자예후평고적개치.방법 회고성분석경병리학진적50례TCL환자,재화료중기급치료결속후18F-FDG PET-CT영상특점.50례환자중,12례우화료중기행PET-CT검사,19례우화료중기급치료결속후균행PET-CT검사,19례우치료결속후행PET-CT검사.근거PET-CT검사결과장환자분위PET-CT양성조화음성조,경과수방31(4～86)개월,분별계산각조환자적무진전생존(PFS)기급총체생존(OS)기,채용Kaplan-Meier생존분석법진행생존분석,각조간적PFS솔급OS솔적비교채용Fisher학절개솔법.결과 31례화료중기18F-FDG PET-CT현상결과양성환자19례,음성환자12례,양성자화음성자중위PFS기분별위8화30개월,1년PFS솔분별위21.1％(4/19)화100.0％(12/12),차이유통계학의의(P＜0.01);중위OS기분별위16화36개월,3년OS솔분별위10.5％(2/19)화66.7％(8/12),차이유통계학의의(P＜0.01).치료결속후18F-FDG PET-CT현상결과양성환자16례,음성환자22례,양성자화음성자중위PFS기분별위10화32개월,1년PFS솔분별위12.5％(2/16)화95.5％(21/22),차이유통계학의의(P＜0.01);중위OS기분별위20화41개월,3년OS솔분별위12.5％(2/16)화54.5％(12/22),차이유통계학의의(P＜0.01).결론 TCL환자화료중기급치료결속후18F-FDG PET-CT검사결과대감측료효급판단예후구유중요의의.
Objective To investigate the prognostic value of interim and post-therapy 18fluorine-fluododeoxyglucose(18F-FDG) PET-CT in patients with T-cell lymphoma.Methods A retrospective analysis was conducted on data from 50 patients diagnosed with T-cell lymphoma(12 patients underwent interim PET-CT only,19 patients underwent interim and post-therapy PET-CT,and the rest 19 patients underwent only post-therapy PET-CT).Interim and post-therapy PET-CT(positive versus negative) were visually interpreted according to the criteria of the International Harmonization Project.The progression-free survival (PFS) and overall survival(OS) of two groups were calculated.We used the Fisher exact test and KaplanMeier testfor data analysis.Results Interim 18F-FDG PET-CT results were positive in 19 cases and negative in 12 cases.The median PFS and OS were 8 months and 16 months,in patients with positive results,versus 30 months and 36 months,in patients with negative results.The 1-year PFS and 3-year OS rates were 21.1％ (4/19) and 10.5％(2/19) in patients with positive results at interim PET/CT versus 100.0％(12/12) and 66.7％ (8/12) in patients with negative results(P＜0.01.Post-therapy 18F-FDG PET-CT results were positive in 16 cases and negative in 22 cases,the median PFS and OS were 10 months and 20 months in patients with positive results versus 32 months and 41 months in patients with negative results.The 1-year PFS and 3-year OS rates were 12.5％(2/16) and 12.5％(2/16),in patients with positive results at post-therapy PET-CT versus 95.5％(21/22) and 54.5％(12/22),in patients with negative results(P＜0.01).Conclusion Both interim PET-CT status and post-therapy PET-CT have significant value in monitoring response to therapy and predicting prognosis for patients with T-cell lymphoma.